Flexion Therapeutics

Transformative Medicine... Where It Matters

  • COVID-19 Update
  • Who We Are
    • Core Principles & Values
    • Executive Committee
    • Board of Directors
    • Corporate Social Responsibility
  • Our Product
  • Our Pipeline
  • Our Science
    • Unmet Need in Osteoarthritis
    • Clinical Trials and Associated Publications
  • News
    • Press Releases
  • Investors
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Analyst Coverage
    • Contact Us
  • Careers
    • Our Culture
    • Benefits
  • Contact
    • Medical Information Request Form
    • Partnering
    • Patient Expanded Access
    • Report a Compliance Matter
  • COVID-19 Update

Our Pipeline

Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA).

Flexion Pipeline

Zilretta FX201 FX301

FX201

(humantakinogene hadenovec)

FX201 is a novel, intra-articular gene therapy product candidate which utilizes a helper-dependent adenovirus (HDAd) vector based on human serotype 5 (Ad5) that is designed to transfer a gene to cells in the joint to produce an anti-inflammatory protein, interleukin-1 receptor antagonist (IL-1Ra), under the control of an inflammation-sensitive promoter. Inflammation is a known cause of pain, and chronic inflammation is thought to play a major role in the progression of OA. By persistently suppressing inflammation, Flexion believes FX201 holds the potential to provide long-term pain relief and functional improvement, and to modify the disease.

FX301

(funapide formulated in a proprietary thermosensitive hydrogel)

FX301 is a locally administered NaV1.7 inhibitor product candidate, known as funapide, formulated for extended-release in a thermosensitive hydrogel. The initial development of FX301 is intended to support administration as a peripheral nerve block for control of post-operative pain. FX301 has the potential to provide effective pain relief while preserving motor function. The company anticipates initiating FX301 clinical trials in 2021.

The information contained on this website reflects Flexion Therapeutics’ clinical development program as of November 19, 2020, and is not intended for promotional purposes. There can be no guarantee that any clinical development program reaches completion or that any indication or investigational therapy receives regulatory approval.

© 2021, Flexion Therapeutics Inc.

781.305.7777

Website Design & Development by Graphic Beans

Terms of Use Sitemap Privacy Policy

Connect with us: LinkedIn-whiteTwitter-whiteGlassdoor-white